MedPath

Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia

Not Applicable
Recruiting
Conditions
Chronic Schizophrenia
Interventions
Device: transcranial direct current stimulation
Registration Number
NCT06349369
Lead Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Brief Summary

The study is a randomized, double-blind, parallel-arm, sham-controlled trial that aims to compare the effects of transcranial direct current stimulation (tDCS) versus sham stimulation on inflammatory markers (IL-6 and TNF-alpha) and clinical outcomes (PANSS, AHRS, CGI-SCH, GAF) in patients with chronic schizophrenia over 10 days of treatment. The primary objective is to assess changes in IL-6 levels, while secondary objectives include evaluating changes in TNF-alpha, symptom scales, and adverse events. The study will be conducted at the psychiatry department of AIIMS Bhubaneswar, with 60 patients aged 18-60 years with moderate-to-severe schizophrenia symptoms randomized to receive either active tDCS (cathode over left temporo-parietal junction, anode over left dorsolateral prefrontal cortex) or sham stimulation. The researchers hope to elucidate the potential immunomodulatory effects of tDCS and its impact on symptoms in chronic schizophrenia, which may lead to more targeted, multifaceted interventions to improve patient outcomes.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
    1. Patients clinically diagnosed with schizophrenia (F20 according to ICD-11) for a period more than 2 years receiving antipsychotics.
  1. Moderate to severe symptoms (PANSS score >75 and/or CGI-SGH score >4) 3. Patients of both sex 18-60 years 4. Right-handed. 5. Legally authorized representative (LAR) giving voluntary written consent for participation in the study.
Exclusion Criteria
    1. Patients with chance of pregnancy. 2. Any psychiatric emergency (e.g. suicidal risk, catatonia, prolonged nutritional deprivation) or others (e.g.: aggression or excitement) 3. Co-morbid neurological disease: i) History of migraine. ii) History of seizure/epilepsy. iii) History of head trauma or organic disease.

    2. Any contraindication to tDCS procedure: i) Injury or local lesion in the scalp/head ii) Metallic implants in the head iii) Implanted brain medical devices 5. Left-handed.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatment grouptranscranial direct current stimulationthe cathode will be located over a point midway between T3 and P3 (left temporo-parietal junction, assumed to correspond to a region including BA 22, 39, 40, 41, and 42, depending on the patient) and the anode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex, assumed to correspond to a region including Brodmann's areas \[BA\] 8, 9, 10, and 46, depending on the patient).The transcranial brain stimulation will be given 2 sessions per day for 10 days, in which 20 minutes of stimulation with an inter-session interval of 3 hours.
Sham control grouptranscranial direct current stimulationTo Maximize the stimulatory effects 1mA current will be applied for the first 30 seconds, to provide the initial sensation of real stimulation and then the current will be stopped, thus minimizing the stimulatory effects.
Primary Outcome Measures
NameTimeMethod
Change in the IL-6 levels10 days
Secondary Outcome Measures
NameTimeMethod
To compare the adverse events reported in both control and intervention groups.5 days and 10 days
Change in the Positive and Negative syndrome Scale5 days and 10 days

score 1- absent symptoms Score 7- extreme symptoms

Change in the Auditory hallucination rating scale5 days and 10 days

score 0- No Auditory hallucination Score 9- Severe Auditory hallucination

Change in the Clinical global impression- Schizophrenia scale5 days and 10 days

score 0- not assessed score 7- extremely ill patients

Change in the TNF alpha levels.10 days
Change in the Global Assessment of Functioning scale5 days and 10 days

score 0- inadequate information score 100- No symptoms

Trial Locations

Locations (1)

AIIMS Bhubaneswar

🇮🇳

Bhubaneswar, Odisha, India

© Copyright 2025. All Rights Reserved by MedPath